Wednesday, January 26, 2011
Dabigatran, and what about its use in Nephrology and Transplantation?
Dabigatran etexilate is an oral direct thrombin inhibitor that has been now approved by FDA as of Oct 2010 for clinical use. Its been FDA approved for stroke prevention in non valvular Atrial Fibrillation. A recent paper in Circulation also listed below, approved it for cardioversion as well. The dosages to be used are: 75mg to 150mg BID and no levels to check and blood thinning effects are similar to warfarin. The RE-LY study presented in NEJM showed it to be superior to warfarin when used at a dose of 150mg and non inferior when a dose of 110mg was used. At a dose of 110mg the rates of stroke and embolism were similar to warfarin and bleeding rates were lower with this agent compared to warfarin. With a dose of 150mg , the rates of stroke and embolism were lower.; the bleeding risks were similar to warfarin. Compared with warfarin, patients on dabigatran 150mg had a 35% reduction in the incidence of stroke, and the rate of major bleeding each year was 3.3% with the new agent and 3.6% per year with warfarin It works as its a direct inhibitor of thrombin. It has an absolute bioavailability of 6.5%, 80% of the given dose is excreted by the kidneys, its serum half-life is 12 to 17 hours. Its precursor drug had hepatic toxicity, this drug so far didn't have that problem.
What is the question at our front? Can we use this agent in our transplant patients who are on immunosuppresion and if there is any interactions?
The other question is in ESRD or CKD patients since this is excreted via the kidney?
One study listed below was to investigate the effect of renal impairment on the pharmacokinetics and pharmacodynamics of dabigatran following administration of a single oral dose of dabigatran etexilate in subjects with renal impairment (150 mg) or end-stage renal disease (ESRD) on maintenance haemodialysis (50 mg). In subjects with severe renal impairment, half life was doubled from 14 hours to 28 hours. As a result AUC was high and activated PTT was also higher in those patients. Hemodialysis removed 62-68% of the dose. Dabigatran etexilate was well tolerated in all groups. The study concluded that "Exposure to dabigatran is increased by renal impairment and correlates with the severity of renal dysfunction. A decrease in the dose and/or an increase in the administration interval in these patients may be appropriate. In patients with ESRD, dabigatran can be partly removed from the plasma by haemodialysis." This is the only study we could find in the literature regarding this drug.
The other question is about transplantation patients. So far no mention about such cases or reports of being used in transplantation patients. Cyclosporine is a p gp inhibitor and based on the interactions data, dabigatran dose reductions might be required if used with calcineurin inhibitors. No interactions were found with MMF, Steroids, Azathioprine or sirolimus.
- ► 2021 (25)
- ► 2020 (32)
- ► 2019 (42)
- ► 2018 (57)
- ► 2017 (52)
- ► 2016 (45)
- ► 2015 (63)
- ► 2014 (95)
- ► 2013 (133)
- ► 2012 (201)
- Pregnancy in Chronic Kidney Disease
- CONSULT ROUNDS: Cetuximab therapy and wasting synd...
- TOPIC DISCUSSION: LEAD and the KIDNEY
- Vitamin D- NEJM Review 2011
- IN THE NEWS- TPA vs Heparin- NEJM Study
- Kidney Disease: Racial Disparities from the Inside...
- Dabigatran, and what about its use in Nephrology a...
- The Transplant Web
- TOPIC DISCUSSION: Blood Urea Nitrogen ( BUN)
- Diabetic Nephropathy Video on You tube
- 2011 Guest Lecture Series (Part 1 of 2): Gerald A...
- TOPIC DISCUSSION: Thiazides and Hyponatremia
- IN THE NEWS--> Storytelling and Hypertension
- Fibrosis with Inflammation at One Year Predicts Tr...
- NSLIJ - Innate B Cell in Humans that Protects Agai...
- IN THE NEWS-->AngII and Metabolic Syndrome
- TOPIC DISCUSSION: Magnesium for pre eclampsia?
- IN THE NEWS:- THE BOLDE Study
- TOPIC DISCUSSION: Paraneoplastic Glomerulopathy
- Informing the Debate: Rates of Kidney Transplantat...
- History of Nephrology: The Korean War 1950-3
- TOPIC DISCUSSION: Cryoglobulin Classification Made...
- CLINICAL CASE 31, ANSWER and SUMMARY
- Quiz 9 Answers
- HISTORY LESSON- Scribner Shunt
- IN THE NEWS --> Cytoresistance and the kidney
- PD University = HD university
- Medicine for residents: urinary calcium and renal ...
- Life After Renal Fellowship Survey Results
- Bisphosphonate Therapy in CKD and ESRD patients
- CONSULT ROUNDS: Amyloidosis vs Light Chain Deposit...
- The Study of Heart and Renal Protection — SHARP Trial
- Can Alcohol Consumption be protective post transpl...
- DID YOU KNOW? Extra renal Podocyte like systems?
- TOPIC DISCUSSION: Low or negative Anion gap!
- ▼ January (35)
- ► 2010 (461)